Globally, More than 100+ Key Companies are Developing Therapies for Ovarian Cancer to Improve the Treatment Scenario

Ovarian cancer is one of the most common cancer in women worldwide and ranks fifth in cancer deaths among women. Ovarian cancer accounts for more deaths than any other female reproductive system cancer. As with most cancers, Ovarian Cancer becomes more common as a person ages. The risk of Ovarian Cancer increases steeply from around 45 years and is greatest in those aged between 75 and 79 years. Between 5 and 15 out of 100 Ovarian Cancers (5 to 15%) are caused by an inherited faulty gene.

"Ovarian Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ovarian Cancer Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Ovarian Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Ovarian Cancer Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer treatment.
Ovarian Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ovarian Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ovarian Cancer Therapeutics Analysis
Globally, more than 100+ key companies are developing therapies for Ovarian Cancer. The companies with Ovarian Cancer drug candidates in the most advanced stage, i.e., phase III, include Genentech.

Some of the key companies actively working in the Ovarian Cancer Therapeutics Market include Genentech, Genmab, AstraZeneca, BioNumerik Pharmaceuticals, On Target Laboratories, Gilead Sciences, Acerta Pharma, MedImmune, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, AB Science, Syndax Pharmaceuticals, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Clovis Oncology, CSPC ZhongQi Pharmaceutical, Immunitor LLC, Ellipses Pharma, Impact Therapeutics, Inc., Eli Lilly and Company, BeiGene, Hoffmann-La Roche, Apexigen, Novartis Oncology, Plexxikon, Jiangxi Qingfeng Pharmaceutical Co. Ltd., PharmaMar, Aprea Therapeutics, VBL Therapeutics, Tesaro, Cristal Therapeutics, Bayer, Pfizer, Hrain Biotechnology Co., Ltd., Regeneron Pharmaceuticals, DCPrime BV, PTC Therapeutics, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Arcus Biosciences, Verastem, Inc., Celsion, and others.

Ovarian Cancer Therapies covered in the report include:
Atezolizumab (Genentech)
Tisotumab Vedotin (Genmab)
Pembrolizumab (Merck)
And Several Other.

Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Ovarian Cancer Current Treatment Patterns
4. Ovarian Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ovarian Cancer Late Stage Products (Phase-III)
7. Ovarian Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ovarian Cancer Discontinued Products
13. Ovarian Cancer Product Profiles
14. Ovarian Cancer Key Companies
15. Ovarian Cancer Key Products
16. Dormant and Discontinued Products
17. Ovarian Cancer Unmet Needs
18. Ovarian Cancer Future Perspectives
19. Ovarian Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.